ASX:TLXBiotechs
Does New TLX597-Tx Data And Pipeline Progression Change The Bull Case For Telix (ASX:TLX)?
In late April 2026, Telix Pharmaceuticals reported Phase 2 OPTIMAL-PSMA dosimetry data for its second-generation prostate cancer candidate TLX597-Tx, showing low radiation uptake in non-target organs and supporting further evaluation in earlier-stage disease, while also progressing a Regeneron collaboration and a European review of its glioma imaging agent TLX101-Px.
These developments highlight how Telix is trying to build an integrated radiopharmaceutical platform, pairing next-generation...